PCP
EW icon

Perbak Capital Partners’s Edwards Lifesciences EW Stock Holding History

Perbak Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,497
Closed -$600K – 90
2026
Q1 		$600K Buy
+7,497
New +$618K 0.15% 161
2025
Q4 		– Sell
-8,238
Closed -$641K – 258
2025
Q3 		$641K Buy
+8,238
New +$644K 0.11% 199

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Perbak Capital Partners's EW Position: Q2 2026 in Review

Perbak Capital Partners sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 7,497 shares — an estimated $600K sold.

Perbak Capital Partners first reported a position in EW in Q3 2025 and held it in 2 quarters. The position peaked at $641K in Q3 2025. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Perbak Capital Partners reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 7,497 Edwards Lifesciences shares in Q2 2026, an estimated $600K.
  • Perbak Capital Partners first reported a position in Edwards Lifesciences in Q3 2025 and held it in 2 quarters.
  • Perbak Capital Partners's Edwards Lifesciences position peaked at $641K in Q3 2025.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.